Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts

• Päätekijät: Ramesh Nimma (Tekijä), Anil Kumar Kalvala (Tekijä), Nilkumar Patel (Tekijä), Sunil Kumar Surapaneni (Tekijä), Li Sun (Tekijä), Rakesh Singh (Tekijä), Ebony Nottingham (Tekijä), Arvind Bagde (Tekijä), Nagavendra Kommineni (Tekijä), Peggy Arthur (Tekijä), Aakash Nathani (Tekijä), David G. Meckes (Tekijä), Mandip Singh (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2022-05-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

The epidermal growth factor receptor (EGFR) is highly expressed in many non-small cell lung cancers (NSCLC), necessitating the use of EGFR-tyrosine kinase inhibitors (TKIs) as first-line treatments. Osimertinib (OSM), a third-generation TKI, is routinely used in clinics, but T790M mutations in exon...